Tamiflu sales soar 203 per cent - Roche

Sales of anti-flu drug Tamiflu soared 203 per cent in the first six months of this year, Swiss pharmaceutical giant Roche said yesterday, contributing to a nine per cent growth in overall sales for the group. Amid the swine flu pandemic, sales of the...

Sales of anti-flu drug Tamiflu soared 203 per cent in the first six months of this year, Swiss pharmaceutical giant Roche said yesterday, contributing to a nine per cent growth in overall sales for the group. Amid the swine flu pandemic, sales of the drug reached one billion Swiss francs (€659 million) in the first half of the year.

Sales to governments and corporations which were stockpiling the drug reached 653 million francs during the period, said Roche.

"Additional government stockpiling orders and increased demand in the retail pharmacy market contributed to the particularly strong sales recorded in the second quarter," it added. Roche said it would be ramping up its production capacity of Tamiflu - one of two drugs recommended by the World Health Organisation to treat the A(H1N1) virus - to 400 million packs annually by next year.

In its first half earnings statement, the group also said that overall sales reached 24 billion Swiss francs, up nine per cent.

Net profit was however down 29 per cent to 4.1 billion Swiss francs due to charges related to the acquisition of Genentech.

Sign up to our free newsletters

Get the best updates straight to your inbox:

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.